SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 5,415.04 |
| Enterprise Value ($M) | 5,253.19 |
| Book Value ($M) | 483.02 |
| Book Value / Share | 8.93 |
| Price / Book | 11.21 |
| NCAV ($M) | 305.41 |
| NCAV / Share | 5.65 |
| Price / NCAV | 17.73 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.07 |
| Return on Assets (ROA) | -0.07 |
| Return on Equity (ROE) | -0.15 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 4.29 |
| Current Ratio | 4.29 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 587.30 |
| Assets | 764.91 |
| Liabilities | 281.89 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Perceptive Advisors Llc | 7.20 | -14.44 | |
| 13G/A | Paradigm Biocapital Advisors LP | 8.90 | 31.20 | |
| 13G/A | Fmr Llc | 12.05 | 20.11 | |
| 13D | Elghandour Rami | 5.00 | ||
| 13G/A | BlackRock, Inc. | 7.90 | 0.00 | |
| 13D/A | Sr One Capital Management, Llc | 4.44 | -25.42 | |
| 13G/A | Suvretta Capital Management, Llc | 5.00 | 3.64 | |
| 13G | BlackRock Inc. | 6.20 | 40.00 | |
| 13G/A | Gilead Sciences Inc | 12.90 | 93.22 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 123,045 | 402,324 | 30.58 | |
| 142,523 | 449,645 | 31.70 | |
| 116,800 | 463,010 | 25.23 | |
| 164,681 | 614,423 | 26.80 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABOS – Acumen Pharmaceuticals, Inc. | ABUS – Arbutus Biopharma Corporation |
| ACAD – ACADIA Pharmaceuticals Inc. | ACRS – Aclaris Therapeutics, Inc. |
| ACT – Enact Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io